Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En åpen, randomisert, multikenter, fase 2-studie av FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for annelinjebehandling av metastatisk, RAS-mutert, mikrosatellitt-stabil (MSS) kolorektalkreft

3. november 2026 oppdatert av: Oncolytics Biotech

En åpen, randomisert, multikenter, fase 2-studie av FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for andrelinje behandling av metastatisk, RAS-mutert, mikrosatellitt-stabil (MSS) kolorektalkreft

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Approximately 60 patients will be randomized 1:1 to the following study arms:

  • Arm A: FOLFIRI + bevacizumab + pelareorep
  • Arm B: FOLFIRI + bevacizumab The primary endpoint is ORR as assessed by the investigator per RECIST 1.1. OS, PFS, and assessment of the safety and tolerability of the study treatment combinations are secondary endpoints. The primary endpoint analysis will be performed after all patients have had at least one tumor assessment following initiation of study treatment or have progressed. The secondary endpoint analyses will take place at EOS.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Name: Reference Study ID Number: REO 033
  • Telefonnummer: +1 (858) 247-7829
  • E-post: REO-033@oncolytics.com

Studiesteder

    • Alabama
      • Homewood, Alabama, Forente stater, 35209
    • California
      • Beverly Hills, California, Forente stater, 90211
        • Rekruttering
        • Clinical Research Advisors (Beverly Hills)
        • Ta kontakt med:
      • Encino, California, Forente stater, 91316
        • Rekruttering
        • Clinical Research Advisors (Encino)
      • Koreatown, California, Forente stater, 90020
        • Rekruttering
        • Clinical Research Advisors (Korea Town)
      • Los Angeles, California, Forente stater, 90033
        • Rekruttering
        • Clinical Research Advisors (Downtown LA)
      • Los Angeles, California, Forente stater, 90048
        • Rekruttering
        • Clinical Research Advisors (West Hollywood)
      • West Covina, California, Forente stater, 91790
        • Rekruttering
        • Clinical Research Advisors (West Covina)
    • Florida
      • Tampa, Florida, Forente stater, 33612
    • Georgia
    • Idaho
      • Post Falls, Idaho, Forente stater, 83854
        • Rekruttering
        • Beacon Cancer Center
        • Ta kontakt med:
    • Illinois
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46250
        • Rekruttering
        • Community Health Network
        • Ta kontakt med:
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Ta kontakt med:
    • New Jersey
      • Florham Park, New Jersey, Forente stater, 07932
        • Rekruttering
        • Summit Health Cancer Center
        • Ta kontakt med:
      • New Brunswick, New Jersey, Forente stater, 08901
        • Rekruttering
        • Rutgers Cancer Institute
        • Ta kontakt med:
    • Ohio
      • Canton, Ohio, Forente stater, 44718
      • Cincinnati, Ohio, Forente stater, 45219
        • Rekruttering
        • University of Cincinnati Medical Center
      • Colombus, Ohio, Forente stater, 43210
        • Rekruttering
        • Ohio State University
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • The University of Texas MD Anderson Cancer Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed cancer of the colon or rectum with documented metastasis
  • Measurable disease per RECIST v. 1.1
  • Not candidates for curative surgery or curative radiation
  • Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin
  • Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
  • Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
  • Tumor confirmed to harbor a known RAS mutation per a standard local testing method
  • ECOG performance status of 0 or 1
  • Patients must have adequate hematological, renal, and hepatic function
  • Female patients of childbearing potential must have a negative pregnancy test
  • Life expectancy of at least 6 months

Exclusion Criteria:

  • Undergone systemic chemotherapy, radiotherapy, or surgery, <4 weeks before study treatment
  • Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment
  • Prior treatment with irinotecan
  • Symptomatic brain metastases
  • Active autoimmune disease
  • Receiving immunosuppressive or myelosuppressive medications
  • Active, uncontrolled infections
  • Known HIV infection or active hepatitis B or C that requires anti-viral treatment
  • History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
  • History of allergy or known hypersensitivity to any of the study drugs, study drug classes,
  • Uncontrolled or severe cardiac disease
  • Received any vaccine within 28 days prior to first study treatment

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm A

Bevacizumab (5 mg/kg) IV infusion

Andre navn:
  • Avastin

irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion

pelareorep 4.5 x 10^10 TCID50 IV infusion

Eksperimentell: Arm B

Bevacizumab (5 mg/kg) IV infusion

Andre navn:
  • Avastin

irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Response Rate (ORR)
Tidsramme: At week 8

Proportion of patients with complete response [CR], partial response [PR] assessed by the investigators and/or central reader according to RECIST v1.1

At week 8

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall Survival (OS) -
Tidsramme: From the date of randomization through long term follow up at two years

OS defined as the time from date of randomization to death from any cause

From the date of randomization through long term follow up at two years
Progression Free Survival (PFS)
Tidsramme: From randomization to objective progression or death from any cause, whichever occurs first, up to two years

Time from randomization to the date of investigator-determined objective progression (according to RECIST 1.1) or death from any cause, whichever occurs first.

From randomization to objective progression or death from any cause, whichever occurs first, up to two years
Disease Control Rate (DCR)
Tidsramme: From randomization to disease progression or death from any cause, whichever occurs first, up to two years

Overall DCR, defined as the number of patients with a best overall response of CR, PR, or SD according to RECIST v. 1.1

From randomization to disease progression or death from any cause, whichever occurs first, up to two years
Duration of Response (DOR)
Tidsramme: From randomization to disease progression or death from any cause, whichever occurs first, up to two years

Time from documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death.

From randomization to disease progression or death from any cause, whichever occurs first, up to two years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. april 2026

Primær fullføring (Antatt)

30. august 2027

Studiet fullført (Antatt)

30. april 2030

Datoer for studieregistrering

Først innsendt

25. februar 2026

Først innsendt som oppfylte QC-kriteriene

25. februar 2026

Først lagt ut (Faktiske)

3. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. november 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • REO 033

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .